ArticleVeterinary medicine and science2026
A Botanical Mixture of Boswellia serrata, Commiphora myrrha, Propolis and Scutellaria baicalensis Reduces Expression of Inflammatory Chemokines in Canine Keratinocytes In Vitro.
Article in Veterinary medicine and science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBotanical ingredients can function as adjunctive therapies for managing inflammatory skin diseases.
objectivesThis study aimed to investigate the anti-inflammatory effects of a mixture of Boswellia serrata, Commiphora myrrha, propolis and Scutellaria baicalensis (YSK-AB) on canine keratinocytes in vitro.
methodsHigh-performance liquid chromatography (HPLC) was used to identify major components of YSK-AB. In addition, to evaluate nitric oxide (NO) production, RAW 264.7 cells were treated with YSK-AB (25, 50, 100 and 200 µg/mL) for 24 h, subsequently stimulated with lipopolysaccharide (1 µg/mL). To analyse the cytotoxic effects of YSK-AB, canine progenitor epidermal keratinocytes (CPEKs) were incubated with YSK-AB for 48 h. To investigate the effects of YSK-AB on cytokine expression, CPEKs were incubated with YSK-AB for 24 h and then stimulated with a mixture of interferon-γ and tumour necrosis factor-α (30 ng/mL each) for 24 h. The enzyme-linked immunosorbent assay (ELISA) was performed to measure chemokine (C-C motif) ligand 2 (CCL2) and CCL5. Real-time polymerase chain reaction (PCR) was used to quantify CCL17 mRNA expression.
resultsHPLC analysis identified four components in YSK‑AB, including 6‑hydroxy‑2,6‑dimethylhepta‑2,4‑dienal, baicalin, galangin and AKBA. CPEKs treated with 100, 150, 200 and 250 µg/mL of YSK‑AB exhibited significantly higher viability than that of the control group. In addition, YSK‑AB treatment (50, 100 and 200 µg/mL) significantly reduced NO production in RAW 264.7 cells. Furthermore, CCL17 mRNA expression and CCL2 and CCL5 protein levels were significantly reduced in YSK‑AB‑treated CPEKs compared with the control.
conclusionsYSK-AB downregulates the expression of chemokines produced by canine keratinocytes and could be a potential novel natural product-derived therapeutic agent for alleviating inflammatory skin diseases in dogs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.